PEDI-Pharm Lab

Paediatrics & Early-life Drug Innovation in Pharmacology

A Targeted Approach

The PEDI-Pharm Lab, led by Dr. Tamorah Lewis, is dedicated to advancing drug safety and efficacy for paediatric and neonatal patients through innovative clinical pharmacology research. Our mission is to bring precision medicine to the neonatal intensive care unit (NICU) and to advance regulatory science that supports evidence-based, safe, and individualized care for children.

Our team is equally committed to embedding principles of justice, equity, diversity, and inclusion (JEDI) principles throughout all aspects of pharmacology research. Our initiatives include:

  • Building a diverse and inclusive research team
  • Conducting advocacy and teaching to disseminate evidence-based strategies of improving racial and ethnic representation in clinical trials and increasing diversity in the biomedical workforce
  • Mentoring and supporting the next generation of physicians and scientists in pharmacology and medicine

Dr. Tamorah Lewis is a physician scientist, Division Head for Clinical Pharmacology and Toxicology at SickKids. In this role, Dr. Lewis helps advance the hospital-wide vision for Precision Child Health and collaborates with multiple clinical divisions for pharmacology research.

Dr. Lewis provides clinical care on the inpatient Clinical Pharmacology consult service and also in the level IV Neonatal ICU at SickKids. Prior to this new role, Dr. Lewis was at Children’s Mercy Kansas City in the Divisions of Neonatology and Pediatric Clinical Pharmacology for 7 years.

Dr. Lewis leads clinical and translational research in neonatal and paediatric pharmacology. The goals of Dr. Lewis’ research program are to bring precision therapeutics to the NICU population. Dr. Lewis’ interests include PBPK and population pharmacokinetic and pharmacodynamic investigations in neonates and children, pertaining to both drugs in common use and drugs under development. Her research focuses on the intersection between ontogeny and pharmacogenetic effects on pharmacology of drugs in infants and neonates. She also aims to bring PK-model informed precision dosing (MIPD) to neonatal and pediatric patient populations.

Research Themes

Research themes explored in the PEDI-Pharm lab

Pharmacoepidemiology

Emerging trends in drug prescribing patterns in children

Paediatric Regulatory Science

Improving drug development for neonates & children

Developmental Pharmacology

How do drug metabolizing enzymes & drug targets develop?

Pharmacogenetics & Personalized Medicine

Identifying the correct drug & dosage for an individual child

Pharmacovigilance

Using ‘big data’ to understand rare adverse drug reactions in children

Discover the Future

Thank you to our funding partners for their generous support:

SickKids Foundation | RareKids-CAN | Azrieli Precision Child Health Partnership Catalyst Program | Canadian Institutes of Health Research (CIHR) | Acceleration Consortium